C12N 2810/6054
Retroviridae
C12N2810/6054 (Retroviridae) appears on 68 US grants and 95 published applications in this corpus.
Search patents in C12N- Granted patents
- 68
- Published applications
- 95
- Assignees
- 81
- Inventors
- 220
- Latest grant
- 16 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1997 | 2 | 0 |
| 1998 | 2 | 0 |
| 1999 | 5 | 0 |
| 2000 | 7 | 0 |
| 2001 | 3 | 1 |
| 2002 | 4 | 4 |
| 2003 | 3 | 8 |
| 2004 | 4 | 4 |
| 2005 | 1 | 7 |
| 2006 | 2 | 7 |
| 2007 | 2 | 2 |
| 2008 | 1 | 7 |
| 2009 | 1 | 5 |
| 2010 | 2 | 6 |
| 2011 | 2 | 1 |
| 2012 | 3 | 3 |
| 2013 | 1 | 2 |
| 2014 | 3 | 6 |
| 2015 | 2 | 3 |
| 2016 | 2 | 2 |
| 2017 | 2 | 4 |
| 2018 | 2 | 5 |
| 2019 | 1 | 6 |
| 2020 | 1 | 2 |
| 2021 | 1 | 3 |
| 2022 | 1 | 0 |
| 2023 | 2 | 2 |
| 2024 | 4 | 3 |
| 2025 | 1 | 0 |
| 2026 | 1 | 2 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Methods of delivering anionic agents in vivo using non-viral nanoparticle-based delivery systems16 Jun 2026US 12,653,905 B2Nanora Pharma Inc.
- Method for improving retroviral transduction and gene editing in hematopoietic stem cells using clyclosporin H and UM1712 Dec 2025US 12,485,187 B2Fondazione Telethon
- Ex vivo antibody production10 Sep 2024US 12,084,681 B2Kling Biotherapeutics B.V.
- Method for improving retroviral transduction and gene editing in hematopoietic stem cells using cyclosporine h (CsH)23 Apr 2024US 11,964,027 B2
- RNA-based delivery systems with levels of control2 Apr 2024US 11,946,066 B2California Institute of Technology
- Pseudotyped viral particles for targeting tcr-expressing cells6 Aug 2026US 2026/0226500 A1Regeneron Pharmaceuticals, Inc.
- Anti-synucleinopathy peptide and methods to treat neurodegenerative diseases29 Jan 2026US 2026/0027179 A1The University of British Columbia
- Ex vivo antibody production26 Dec 2024US 2024/0425566 A1Kling Biotherapeutics B.V.
- Gene therapy24 Oct 2024US 2024/0350661 A1Fondazione Telethon Ets
- Methods of delivering anionic agents in vivo using non-viral nanoparticle-based delivery systems16 May 2024US 2024/0156984 A1Nanora Pharma Inc.
Most cited
By later US patents
- Retroviral vectors comprising a functional splice donor site and a functional splice acceptor site52US 7,303,910 B2Oxford Biomedica (UK) Limited · 2007
- Chimeric Gag pseudovirions48US 6,099,847 AThe United States of America as represented by the Department of Health and Human Services · 2000
- Receptor-binding pocket mutants of influenza a virus hemagglutinin for use in targeted gene delivery44US 6,416,997 B1The Trustees of the University of Pennsylvania · 2002
- Peptide-enhanced transfections44US 8,058,068 B2Life Technologies Corporation · 2011
- Fusion glycoproteins27US 5,643,756 AThe Public Health Research Institute of the City of New York, Inc. · 1997